At Possis, we’re leaders. We’ve pioneered the leading technology to quickly, safely and effectively remove intra-vascular blood clots (thrombus). Our purpose is simple: save the lives and limbs of patients who suffer from these circulation-blocking clots.

Today, our market-leading AngioJet® technology is FDA approved for use in three vascular territories of the body. Our goal moving forward is to expand the use of AngioJet thrombectomy throughout the vascular system – including new areas such as treating deep vein thrombosis (DVT), pulmonary embolism (PE) and ischemic stroke. In addition, we are looking beyond our current thrombectomy markets and focusing on new products that address unmet needs in the broader endovascular treatment market. These new products will come from internal development efforts and partnerships with other companies.

With proven core technologies, a strong pipeline of new products, cutting-edge clinical science and a well-defined path for future growth, we’re ahead, clearly. And we plan to stay there.

Read Letter to Shareholders.